Apollo Ingredients Ltd
₹ 132
-1.97%
12 Aug
3:32 p.m.
About
Incorporated in 1980, Apollo Ingredients Ltd is
in the business of providing healthcare solutions[1]
Key Points
- Market Cap ₹ 137 Cr.
- Current Price ₹ 132
- High / Low ₹ 146 / 5.43
- Stock P/E 63.0
- Book Value ₹ 6.72
- Dividend Yield 0.00 %
- ROCE 22.9 %
- ROE 17.2 %
- Face Value ₹ 5.00
Pros
- Company is almost debt free.
Cons
- Stock is trading at 19.7 times its book value
- Though the company is reporting repeated profits, it is not paying out dividend
- Company has a low return on equity of 13.4% over last 3 years.
- Debtor days have increased from 27.8 to 42.5 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Loading peers table ...
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 0.40 | 0.00 | 0.00 | 0.00 | 0.00 | 4.34 | 4.58 | 2.37 | 0.00 | 1.00 | 3.07 | 4.90 | 9.62 | |
| 0.51 | 0.17 | 0.17 | 0.17 | 0.17 | 4.26 | 4.45 | 2.41 | 0.10 | 0.92 | 2.95 | 3.98 | 7.34 | |
| Operating Profit | -0.11 | -0.17 | -0.17 | -0.17 | -0.17 | 0.08 | 0.13 | -0.04 | -0.10 | 0.08 | 0.12 | 0.92 | 2.28 |
| OPM % | -27.50% | 1.84% | 2.84% | -1.69% | 8.00% | 3.91% | 18.78% | 23.70% | |||||
| 0.19 | 0.12 | 0.12 | 0.11 | 0.10 | 0.11 | 0.14 | 0.12 | 0.03 | 0.00 | 0.01 | 0.13 | 0.07 | |
| Interest | 0.09 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.10 | 0.18 |
| Profit before tax | -0.01 | -0.05 | -0.05 | -0.06 | -0.07 | 0.19 | 0.27 | 0.08 | -0.07 | 0.08 | 0.13 | 0.95 | 2.17 |
| Tax % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 15.79% | 22.22% | 25.00% | 0.00% | 25.00% | 23.08% | 26.32% | |
| -0.01 | -0.05 | -0.05 | -0.06 | -0.07 | 0.16 | 0.21 | 0.06 | -0.07 | 0.06 | 0.10 | 0.71 | 2.18 | |
| EPS in Rs | 0.06 | -0.07 | 0.06 | 0.10 | 0.68 | 2.10 | |||||||
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 1% |
| 3 Years: | % |
| TTM: | 206% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 32% |
| 5 Years: | 28% |
| 3 Years: | 130% |
| TTM: | 10800% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | 8% |
| 5 Years: | 10% |
| 3 Years: | 13% |
| Last Year: | 17% |
Balance Sheet
Figures in Rs. Crores
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 0.20 | 0.20 | 0.20 | 0.20 | 0.20 | 0.20 | 0.20 | 0.20 | 0.20 | 0.20 | 0.20 | 5.20 |
| Reserves | 1.00 | 0.95 | 0.69 | 0.63 | 0.56 | 0.72 | 0.93 | 0.99 | 0.92 | 0.98 | 1.08 | 1.79 |
| 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.03 | |
| 0.20 | 0.01 | 0.01 | 0.01 | 0.01 | 0.10 | 0.01 | 0.02 | 0.04 | 0.54 | 0.38 | 0.20 | |
| Total Liabilities | 1.40 | 1.16 | 0.90 | 0.84 | 0.77 | 1.02 | 1.14 | 1.21 | 1.16 | 1.72 | 1.67 | 7.22 |
| 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2.90 | |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.21 | 0.21 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| 1.19 | 0.95 | 0.90 | 0.84 | 0.77 | 1.02 | 1.14 | 1.21 | 1.16 | 1.72 | 1.67 | 4.32 | |
| Total Assets | 1.40 | 1.16 | 0.90 | 0.84 | 0.77 | 1.02 | 1.14 | 1.21 | 1.16 | 1.72 | 1.67 | 7.22 |
Cash Flows
Figures in Rs. Crores
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -0.01 | 0.01 | 0.00 | 0.00 | -0.01 | 0.11 | -0.04 | 0.01 | 0.10 | 1.47 | -0.12 | 0.09 | |
| 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -3.00 | |
| 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.00 | 0.00 | 5.00 | |
| Net Cash Flow | -0.01 | 0.01 | 0.00 | 0.00 | -0.01 | 0.11 | -0.04 | 0.01 | 0.11 | 1.47 | -0.12 | 2.09 |
| Free Cash Flow | -0.01 | 0.01 | 0.00 | 0.00 | -0.01 | 0.11 | -0.04 | 0.01 | 0.10 | 1.47 | -0.12 | -2.91 |
| CFO/OP | 9% | -6% | 0% | 0% | 6% | 175% | 15% | -75% | -100% | 1,838% | -75% | 37% |
Ratios
Figures in Rs. Crores
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 13.08 | 42.46 | |||||
| Inventory Days | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Days Payable | ||||||||||||
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 13.08 | 42.46 | |||||
| Working Capital Days | 894.25 | 66.44 | 82.88 | 166.33 | -164.25 | -34.48 | 32.78 | |||||
| ROCE % | 6.67% | -4.26% | -4.90% | -6.98% | -8.81% | 22.62% | 26.34% | 6.90% | -6.06% | 6.96% | 10.53% | 22.86% |
Insights
In beta| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Soya DOC (De-oiled Cake) Sales Volume tons |
|
|||||||||
| Soya Husk Sales Volume tons |
||||||||||
| Number of Permanent Employees count |
||||||||||
Requires Premium
Requires Premium
Extracted by Screener AI
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
- We enclose herewith the copies of newspaper advertisement published of standalone unaudited financial statement for the quarter ended 30th June 2026 in the following newspaper. …
-
Board Meeting Outcome for Outcome Of The Board Meeting- Pursuant To Regulation 30 Of The SEBI (LODR) Regulations, 2015.
- Board approved Q1 FY2026 unaudited results; revenue 526.87 lakh, PAT 121.62 lakh, and appointed media agency.
-
Board Meeting Intimation for Intimation Of The Board Meeting Of The Company.
- Board meeting on 10 Aug 2026 to consider Q1 FY27 unaudited financial results.
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
- Submitted Regulation 74(5) certificate for quarter ended 30 June 2026.
- Shareholder Meeting / Postal Ballot-Scrutinizer''s Report
Annual reports
-
Financial Year 2026
from bse
-
Financial Year 2025
from bse
-
Financial Year 2024
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
Business Overview:[1]
AIL (formerly Indsoya Ltd) is an integrated healthcare solutions provider focusing on the manufacture, import, and export of Ayurvedic, Homoeopathic, and Allopathic medicines. The company is also expanding into setting up and managing hospitals, diagnostic and wellness centres, and pathology labs, while offering value-added services such as clinical audits, hospital consultancy, and healthcare staffing solutions. It aims to leverage opportunities across traditional and modern medical systems, both in India and international markets.